US20100061932A1 - Peptides useful as cell-penetrating peptides - Google Patents

Peptides useful as cell-penetrating peptides Download PDF

Info

Publication number
US20100061932A1
US20100061932A1 US12/159,226 US15922606A US2010061932A1 US 20100061932 A1 US20100061932 A1 US 20100061932A1 US 15922606 A US15922606 A US 15922606A US 2010061932 A1 US2010061932 A1 US 2010061932A1
Authority
US
United States
Prior art keywords
peptide
seq
amino acid
acid sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/159,226
Other languages
English (en)
Inventor
Roland Brock
Rainer Fischer
Mariola Fotin-Mleczek
Hansjoerg Hufnagel
Norbert Windhab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Roehm GmbH
Original Assignee
Evonik Roehm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm GmbH filed Critical Evonik Roehm GmbH
Assigned to EVONIK ROEHM GMBH reassignment EVONIK ROEHM GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WINDHAB, NORBERT, HUFNAGEL, HANSJOERG, FOTIN-MLECZEK, MARIOLA, FISCHER, RAINER, BROCK, ROLAND
Publication of US20100061932A1 publication Critical patent/US20100061932A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Definitions

  • the peptides according to the present invention form a complex together with a cargo molecule.
  • cargo molecule may be any cargo molecule as defined herein.
  • the complex can be either a covalent or a non-covalent complex comprising at least one peptide according to the present invention and at least one cargo molecule. It is also within in the present invention that the complex comprises more than one peptide according to the present invention, i. e. a plurality of such peptides, whereby the plurality of the peptides may comprise a plurality of the same or of different peptides. Also, the complex according to the present invention may also comprise more than one cargo molecule, whereby the plurality of the cargo molecules may comprise a plurality of the same or of different cargo molecules.
  • compositions according to the present invention may also be formulated as a depot preparation.
  • Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compositions may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil), or as part of a solid or semi-solid implant that may or may not be auto-degrading in the body, or ion exchange resins, or one or more components of the composition can be formulated as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/159,226 2005-12-30 2006-10-25 Peptides useful as cell-penetrating peptides Abandoned US20100061932A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05028755 2005-12-30
EP05028755.6 2005-12-30
PCT/EP2006/010271 WO2007076904A1 (en) 2005-12-30 2006-10-25 Peptides useful as cell-penetrating peptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/010271 A-371-Of-International WO2007076904A1 (en) 2005-12-30 2006-10-25 Peptides useful as cell-penetrating peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/557,706 Division US9403884B2 (en) 2005-12-30 2012-07-25 Peptides useful as cell-penetrating peptides

Publications (1)

Publication Number Publication Date
US20100061932A1 true US20100061932A1 (en) 2010-03-11

Family

ID=37491778

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/159,226 Abandoned US20100061932A1 (en) 2005-12-30 2006-10-25 Peptides useful as cell-penetrating peptides
US13/557,706 Active 2028-03-11 US9403884B2 (en) 2005-12-30 2012-07-25 Peptides useful as cell-penetrating peptides
US14/955,696 Abandoned US20160151504A1 (en) 2005-12-30 2015-12-01 Peptides useful as cell-penetrating peptides

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/557,706 Active 2028-03-11 US9403884B2 (en) 2005-12-30 2012-07-25 Peptides useful as cell-penetrating peptides
US14/955,696 Abandoned US20160151504A1 (en) 2005-12-30 2015-12-01 Peptides useful as cell-penetrating peptides

Country Status (16)

Country Link
US (3) US20100061932A1 (ja)
EP (1) EP1966240B3 (ja)
JP (1) JP5264502B2 (ja)
KR (1) KR101317100B1 (ja)
CN (1) CN101395180B (ja)
AT (1) ATE501169T1 (ja)
AU (1) AU2006332193B2 (ja)
BR (1) BRPI0620806B8 (ja)
CA (1) CA2646833C (ja)
DE (1) DE602006020617D1 (ja)
ES (1) ES2361621T7 (ja)
IL (1) IL192131A (ja)
MX (1) MX2008008548A (ja)
PL (1) PL1966240T6 (ja)
SI (1) SI1966240T1 (ja)
WO (1) WO2007076904A1 (ja)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322862A1 (en) * 2009-06-22 2010-12-23 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
WO2012166585A2 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
WO2013052058A1 (en) * 2011-10-07 2013-04-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
CN103169982A (zh) * 2011-12-23 2013-06-26 中国科学院上海药物研究所 生物活性肽修饰的纳米银及其制备方法和用途
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
RU2575603C2 (ru) * 2010-07-30 2016-02-20 Куревак Гмбх Получение комплексов нуклеиновых кислот и поперечно сшитых дисульфидными связями катионных компонентов, предназначенных для трансфекции и иммуностимуляции
US9724422B2 (en) 2010-11-26 2017-08-08 Evonik Roehm Gmbh Human lactoferrin derived peptide for use as an antigen masking agent
WO2018204392A1 (en) 2017-05-02 2018-11-08 Stanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
WO2020161602A1 (en) 2019-02-04 2020-08-13 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
US10793603B2 (en) * 2015-02-27 2020-10-06 Josho Gakuen Educational Foundation Polysaccharide derivative having membrane-permeable peptide chain
US11052053B2 (en) 2018-05-08 2021-07-06 Evonik Operations Gmbh Nanoparticle comprising a bio-resorbable polyester, a hydrophilic polymer and an acylated human lactoferrin-derived peptide

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005051366A1 (de) 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
EP2050461A1 (en) * 2007-10-19 2009-04-22 PharmaSurgics in Sweden AB Peptides based on the sequence of human lactoferrin and their use
EP2090584A1 (en) * 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
CA2716565C (en) * 2008-02-28 2017-09-12 Toray Industries, Inc. Pharmaceutical composition for transnasal administration
CN102686603B (zh) * 2009-12-14 2014-12-17 国立大学法人北海道大学 对脂质膜结构体赋予细胞透过能力和/或增强脂质膜结构体的细胞透过能力的肽、以及含有与这些肽结合了的脂质作为构成脂质的具有细胞透过能力或细胞透过能力得到增强的脂质膜结构体
WO2011084061A1 (en) 2010-01-08 2011-07-14 Universitair Medisch Centrum St. Radboud Cpp (cell penetrating peptide) and its uses
FR2955773B1 (fr) * 2010-02-01 2017-05-26 Commissariat A L'energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
CN102091036A (zh) * 2011-01-10 2011-06-15 中国药科大学 一种含有抗肿瘤药物的复合脂质体及其制备方法和用途
CN102174078A (zh) * 2011-01-10 2011-09-07 中国药科大学 肿瘤细胞选择性穿膜肽的应用
CN102153629B (zh) * 2011-01-20 2013-07-24 华中科技大学 一种短肽及其应用
CN102988295B (zh) * 2011-09-09 2015-07-29 复旦大学 一种穿膜肽修饰的纳米粒及其制备方法
CN102993296A (zh) * 2011-09-14 2013-03-27 广州格拉姆生物科技有限公司 牛乳铁蛋白肽及其制备方法
DE102011055229A1 (de) 2011-11-10 2013-05-16 Evonik Degussa Gmbh Verfahren zur Bereitstellung von Regelleistung mit einem Energiespeicher unter Ausnutzung von Toleranzen bei der Bestimmung der Frequenzabweichung
DE102011055231A1 (de) * 2011-11-10 2013-05-16 Evonik Industries Ag Verfahren zur Bereitstellung von Regelleistung
CN110251682B (zh) 2011-11-24 2022-12-06 苏州宝时得电动工具有限公司 多肽序列设计及其在多肽介导的siRNA传递中的应用
CN103382217B (zh) * 2012-12-11 2015-05-27 任发政 穿膜肽和药物组合物及其制备方法和应用
US9642895B2 (en) 2013-08-12 2017-05-09 3M Innovative Properties Company Peptides for enhancing transdermal delivery
WO2015075747A1 (en) * 2013-11-19 2015-05-28 Council Of Scientific And Industrial Research Cell-penetrating peptide for biomolecule delivery
KR102532559B1 (ko) 2013-12-12 2023-05-16 라이프 테크놀로지스 코포레이션 형질감염을 개선하는 막 투과 펩타이드 및 조성물 그리고 이들을 사용하는 방법
CN103784406A (zh) * 2014-01-20 2014-05-14 同济大学 一种偶联穿膜肽和mmp酶切位点的纳米颗粒
KR101647804B1 (ko) * 2015-06-24 2016-08-11 한국과학기술연구원 신규 세포투과 펩타이드 및 이의 용도
CN108456254B (zh) * 2017-02-20 2021-06-01 中国科学院上海药物研究所 一种tcs-穿膜肽-肿瘤蛋白酶底物肽融合蛋白、其制备方法和用途
CN108101966B (zh) * 2017-12-26 2020-10-27 暨南大学 基于细胞穿膜肽的氧化还原敏感多肽及其在疫苗载体中的应用
CN111499759B (zh) * 2019-01-31 2022-12-20 上海科技大学 一种具有细胞穿膜性的锌指蛋白-乳铁蛋白融合蛋白质及其制备与应用
CN110078834B (zh) * 2019-05-05 2021-07-30 华中科技大学 一种类短肽、辅助透膜剂及其应用
WO2021093881A1 (zh) * 2019-11-14 2021-05-20 上海鑫湾生物科技有限公司 用于调控酸性环境免疫应答的组合物、其制备方法和用途
WO2023186757A1 (en) 2022-03-30 2023-10-05 Evonik Operations Gmbh Formulations composed of cationic lipids and poly(lactic-co-glycolic acid) for the delivery of polynucleotides into cells
WO2024079331A1 (en) * 2022-10-13 2024-04-18 Stichting Radboud Universitair Medisch Centrum A complex comprising a cargo and a targeting moiety binding intelectin-1

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304633A (en) * 1990-09-07 1994-04-19 Morinaga Milk Industry Co., Ltd. Fragments of lactoferrin having potent antimicrobial activity
US5741957A (en) * 1989-12-01 1998-04-21 Pharming B.V. Transgenic bovine
US5804555A (en) * 1992-08-07 1998-09-08 Morinaga Milk Industry Co., Ltd. Antioxidant
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6890902B2 (en) * 1998-08-28 2005-05-10 Alpharma As Cytotoxic modified lactoferrin peptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0533838T3 (da) 1990-06-11 1998-02-23 Nexstar Pharmaceuticals Inc Nukleinsyreligander
JP3312946B2 (ja) * 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
SE9804614A0 (en) * 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
US6423509B1 (en) * 1998-07-15 2002-07-23 Samyang Genex Corporation Pichia pastoris strain for producing lactoferrin and methods of use
WO2000004132A1 (en) * 1998-07-15 2000-01-27 Samyang Genex Corporation Mass production method of lactoferrin polypeptide from yeast and useful microorganism thereof
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
PT2796553T (pt) 2000-03-30 2019-09-27 Massachusetts Inst Technology Mediadores de interferência de arn específicos de sequência de arn
RU2197987C2 (ru) * 2000-07-07 2003-02-10 Закрытое акционерное общество "АСГЛ-Исследовательские Лаборатории" Носитель чужеродной генетической информации для генной терапии

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741957A (en) * 1989-12-01 1998-04-21 Pharming B.V. Transgenic bovine
US6066725A (en) * 1989-12-01 2000-05-23 Pharming B.V. Production of recombinant polypeptides by bovine species and transgenic methods
US5304633A (en) * 1990-09-07 1994-04-19 Morinaga Milk Industry Co., Ltd. Fragments of lactoferrin having potent antimicrobial activity
US5804555A (en) * 1992-08-07 1998-09-08 Morinaga Milk Industry Co., Ltd. Antioxidant
US6890902B2 (en) * 1998-08-28 2005-05-10 Alpharma As Cytotoxic modified lactoferrin peptides
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Aguilera, O. (FEBS Letters (1999), 462(3), 273-277) *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005540A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
US11059718B2 (en) 2009-06-22 2021-07-13 Sanford-Burnham Medical Research Institute Methods and compositions using peptides and proteins with C-terminal elements
US10370245B2 (en) 2009-06-22 2019-08-06 Sanford-Burnham Medical Research Institute Methods and compositions using peptides and proteins with C-terminal elements
US20100322862A1 (en) * 2009-06-22 2010-12-23 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
RU2575603C2 (ru) * 2010-07-30 2016-02-20 Куревак Гмбх Получение комплексов нуклеиновых кислот и поперечно сшитых дисульфидными связями катионных компонентов, предназначенных для трансфекции и иммуностимуляции
US9724422B2 (en) 2010-11-26 2017-08-08 Evonik Roehm Gmbh Human lactoferrin derived peptide for use as an antigen masking agent
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
WO2012166585A2 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US9556224B2 (en) 2011-10-07 2017-01-31 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US10206974B2 (en) 2011-10-07 2019-02-19 Morehouse School Of Medicine Antimicrobial compositions and method of use thereof
WO2013052058A1 (en) * 2011-10-07 2013-04-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US11304991B2 (en) 2011-10-07 2022-04-19 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
CN103169982A (zh) * 2011-12-23 2013-06-26 中国科学院上海药物研究所 生物活性肽修饰的纳米银及其制备方法和用途
US10793603B2 (en) * 2015-02-27 2020-10-06 Josho Gakuen Educational Foundation Polysaccharide derivative having membrane-permeable peptide chain
WO2018204392A1 (en) 2017-05-02 2018-11-08 Stanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
US11052053B2 (en) 2018-05-08 2021-07-06 Evonik Operations Gmbh Nanoparticle comprising a bio-resorbable polyester, a hydrophilic polymer and an acylated human lactoferrin-derived peptide
WO2020161602A1 (en) 2019-02-04 2020-08-13 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof

Also Published As

Publication number Publication date
KR20080091120A (ko) 2008-10-09
CA2646833C (en) 2019-07-30
US20130108662A1 (en) 2013-05-02
AU2006332193A1 (en) 2007-07-12
CN101395180A (zh) 2009-03-25
PL1966240T3 (pl) 2011-08-31
SI1966240T1 (sl) 2011-06-30
ES2361621T7 (es) 2012-06-14
CN101395180B (zh) 2016-06-22
MX2008008548A (es) 2008-09-10
KR101317100B1 (ko) 2013-10-15
EP1966240B3 (en) 2011-12-28
BRPI0620806B1 (pt) 2017-12-05
EP1966240A1 (en) 2008-09-10
DE602006020617D1 (de) 2011-04-21
ES2361621T3 (es) 2011-06-20
JP5264502B2 (ja) 2013-08-14
AU2006332193B2 (en) 2012-06-28
ATE501169T1 (de) 2011-03-15
WO2007076904A1 (en) 2007-07-12
PL1966240T6 (pl) 2012-05-31
BRPI0620806A2 (pt) 2011-11-22
JP2009521908A (ja) 2009-06-11
US20160151504A1 (en) 2016-06-02
US9403884B2 (en) 2016-08-02
IL192131A0 (en) 2008-12-29
EP1966240B1 (en) 2011-03-09
BRPI0620806B8 (pt) 2022-07-05
IL192131A (en) 2011-10-31
CA2646833A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
US9403884B2 (en) Peptides useful as cell-penetrating peptides
JP7328375B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP6697028B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
Magzoub et al. Cell-penetrating peptides: small from inception to application
AU2011244107B2 (en) Peptide derivatives, preparation thereof and uses thereof as vectors
KR101590674B1 (ko) 세포-투과 펩티드 및 이의 용도
JP2006514602A5 (ja)
US9439975B2 (en) Small efficient cell penetrating peptides derived from the scorpion toxin maurocalcine
NZ521563A (en) Peptide conjugates for drug delivery
KR101898502B1 (ko) 인슐린-유사 성장 인자 1 수용체 결합 펩티드
Shinga et al. L17ER4: A cell-permeable attenuated cationic amphiphilic lytic peptide
EP1651670A2 (en) Novel therapeutic fusion proteins
US20120289472A1 (en) Molecules capable of inducing cell death by targeting the mitochondria and applications thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: EVONIK ROEHM GMBH,GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BROCK, ROLAND;FISCHER, RAINER;FOTIN-MLECZEK, MARIOLA;AND OTHERS;SIGNING DATES FROM 20080911 TO 20081106;REEL/FRAME:021905/0455

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION